Volume 11, Abstract Book BHS, February 2020

Index

ABSTRACTS

O.1 Real World Population-Based Exploration of the Pathology Subtyping and Treatment-Modalities of Diffuse Large B-Cell Lymphoma in Belgium in Relation to Survival

W. Daneels, M. Rosskamp, G. Macq, E.I. Saadoon, A. De Geyndt, F. Offner, H. Antoine-Poirel


O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

N. Vandewalle, P. Vlummens, N. De Beule, S. Faict, I. Oudaert, K. Maes, E. De Bruyne, E. Menu, K. Vanderkerken, K. De Veirman


O.3 Palliative cytoreduction with low dose intravenous melphalan in patients with acute myeloid leukemia refractory to prior treatment

E. De Backer, D. Deeren


O.4 An in-depth investigation of the causes of treatment failure in AML

S. Bonte, S. Van Gassen, A. Couckuyt, V. Janda, I. Moors, A. Delie, S. Kennes, J. Philippé, Y. Saeys, T. Kerre


O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation - a multicenter prospective study

S. Servais, F. Baron, C. Lechanteur, E. Baudoux, A. Briquet, D. Selleslag, J. Maertens, X. Poiré, W. Schroyens, C. Graux, A. De Becker, R. Schots, P. Zachée, A. Ory, J. Herman, T. Kerre, Y. Beguin


PP.03 Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring: a standardized approach with underappreciated potential

Lennart Raman, Malaïka Van Der Linden, Ciel De Vriendt, Bliede Van Den Broeck, Kristoff Muylle, Dries Deeren, Kathleen Claes, Björn Menten, Fritz Offner, Jo Van Dorpe


P.39 A case report of functional vitamin B12 deficiency due to recreational nitrous oxide abuse: Who is laughing now?

S. De Bruijn, J.W.J. Van Esser, T. Ermens


PP.02 Mild Cognitive Impairment, Hypoalbuminemia, High Crp And Gi Co-Morbidities: A Frailty Score That Identifies Older Patients With Malignant Hemopathies Who Don't Benefit From Chemotherapy

Vincent Thibaud, Fulvio Massaro, Adriano Salaroli, Chloe Spilleboudt, Marie Vercruyssen, Laurence Deneve, Cindy Kenis, Hans Wildiers, Thierry Pepersack, Thierry Lamy de la Chapelle, Dominique Bron


PP.01 The role of the de novo DNA methyltransferase DNMT3B in multiple myeloma cell survival and drug resistance

C. Muylaert, E. De Bruyne, P. Vlummens, K. Maes, K. De Veirman, E. Menu, K. Vanderkerken


P.46 Hepatitis E management in allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients: a case report

G. Crochet, M. Bourgeois, E. Collinge, H. Vellemans, M. André, A. Sonet, C. Graux


P.45 Development of a knowledge test on Immuno-T, a motion comic explaining immunotherapy to patients and their caregivers

W. Vandemoortele, G. Vanbutsele, M. Valcke, T. Kerre


P.44 Donor cell-derived acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: molecular confirmation by next-generation sequencing

L. Nevejan, D. Selleslag, S. Huygens, B. Cauwelier, J. Emmerechts, H. Devos


P.43 Alectinib-associated low grade hemolysis: unknown adverse reaction

N. Makki, I. Geerts, E. Vermeulen, J. Moerman, A. Van Den Bergh, M. Criel


P.42 Acquired von Willebrand disease following marginal zone lymphoma relapse: a case report

F. Verbeke, P. Decruyenaere, P. Vlummens, A. Vantilborgh, K. Devreese


P.41 Bone marrow hot pockets mimicking sclerotic bone metastases in a patient with aplastic anemia

E. Janssens, J. Van Dorpe, V. Van Hende, I. Moors, P. Vlummens, C. De Vriendt


P.40 Impact of the WPC channel of the Sysmex XN-9100 system in the reduction of false positive flags in paediatric samples

S. Blomme, N. Boeckx, H. Claerhout, C. Brusselmans, C. Van Laer


P.36 Phase 2, open-label, multicenter study to evaluate the efficacy and safety of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement (FIGHT-203)

T. Devos, J. Gotlib, E. Asatiani, C. Walker, H. Zhen, S. Verstovsek


PP.03.2 Improvement of antibody-induced cell death in multiple myeloma

M. Lejeune, E. Duray, C. Zhang, S. Dubois, Y. Beguin, W. Wels, J. Caers


PP.04 Loss of the tumor suppressor RASSF4 is associated with aggressive disease and poor outcome in Diffuse Large B Cell Lymphoma

Michiel De Coster, Elke De Bruyne, Philip Vlummens, Ken Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken


PP.05 Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Filip Callewaert, Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna Kremer Hovinga, Ara Metjian, Javier De la Rubia, Katerina Pavenski


PP.06 Capillary zone electrophoresis measured HbA2 aiding in diagnosis of underlying a-thalassemia in the presence of HbS

Eveline Vancraeynest


PP.07 Blood products and Hematopoietic Progenitor Cells (HPC) Hepatitis E screening: current European practices and guidelines

Marc Bourgeois, Nathalie Ausselet, A. Marot, Elodie Collinge, Julien Depaus, Bérangère Devalet, H. Vellemans, Anne Sonet, G. Crochet, Marc André, Florence Desquesnes, Carlos Graux


PP.08 Treatment of a patient with severe cytomegalovirus (CMV) infection after allogeneic haploidentical stem cell transplantation with donor CMV specific T cells

Joline Ingels, Saskia De Smet, Kelly Heyns, Nele Lootens, Jonas Segaert, Karim Vermaelen, Evelyne Willems, Etienne Baudoux, Tessa Kerre, Frédéric Baron, Bart Vandekerckhove


PP.09 Hemophagocytic lymphohistiocytosis induced by visceral leishmaniasis

Gaëlle Stevens, An Vanacker, Bart Maes, Lien Deleu


PP.10 Cyclophosphamide prevents xenogeneic graft-versus-host disease, without abrogating graft-versus-leukemia effects

Caroline Ritacco, Gregory Ehx, Lorenzo Canti, Sophie Dubois, Benoit Vandenhove, Justine Courtois, Sophie Servais, Yves Beguin, Stéphanie Humblet-Baron, Frédéric Baron


PP.11 Origin and homeostasis of regulatory T cells in chronic Graft-versus-Host Disease

Lorenzo Canti, Ludovic Belle, Gregory Ehx, Gilles Fransolet, Adeline Rosu, Christopher Desmet, Yves Beguin, Stéphanie Humblet-Baron, Frédéric Baron


PP.12 Analysis of differences in preventive measures after high-dose cyclophosphamide among Belgian stem cell transplant centres

Eva De Backer, Dries Deeren


PP.13 Improvement of antibody-induced cell death in multiple myeloma

Margaux Lejeune, Elodie Duray, Congcong Zhang, Sophie Dubois, Yves Beguin, Winfried Wels, Jo Caers


PP.14 Immunophenotypic and molecular features of cuplike morphology in AML

Annelies Louwagie, Barbara Cauwelier, Helena Devos, Jan Emmerechts


P.37 A Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm without Skin Lesions: A Case Report

M. Metsers, N. Steinfort, E. Heylen, P. De schouwer, K.L. Wu


P.15 Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The Lymphoma Study Association (LYSA) Registry Data

M. André, F. Le Bras, P. Gaulard, C. Haioun, C. Laurent, M. Croix, J. Bonnefoy, F. Bouabbas, V. Fataccioli, C. Bonnet


P.16 Malignant invasion of the cerebrospinal fluid in patients with a haematological malignancy: a single center retrospective study

L. Smets, H. Claerhout, N. Boeckx


P.17 Feasibility of next generation flow for minimal residual disease in multiple myeloma on a BD FACS Lyric flowcytometer

H. Claerhout, B. Timmermans, M. Delforge, S. Vandoninck, N. Boeckx


P.18 Daratumumab therapy in patients with immunoglobulin light chain amyloidosis, a single center experience

F. Andreozzi, I. Dufour, A. Sogorb, S. Chabert, G. Verstraete, J. Raedemaeker, L. Bamps, S. Bailly, F. Jamar, F. Lecouvet, A. Camboni, J-P. Defour, A-C. Pouleur, J. Morelle, M-C. Vekemans


P.19 DCEP as a salvage chemotherapy regimen for heavily pretreated multiple myeloma with intention to autograft: single center experience between 2011 and 2018

K. Maes, A. Vantilborgh, P. Vlummens


P.20 Crystalcryoglobulin-induced kidney disease: a case report

S. Leflot


P.21 Disseminated nocardiosis in a patient with multiple myeloma treated with bortezomib, thalidomide and dexamethasone

E. De Backer, P. Vlummens, R. Callens, I. Moors


P.22 AL amyloidosis revealed by polyarthritis

K. Bennis, T. Schubert, F. Jamar, D. Maisin, A. Camboni, S. Aydin, F. Lecouvet, M-C. Vekemans


P.23 An aggressive, acute onset intravascular large B-cell lymphoma presenting with marked peripheral erythroblastosis: a case report

M. Mylemans, E. Vermeulen, H. Maes, M. Criel, I. Geerts


P.24 Rare morphologic phenomena in plasma cell dyscrasia: report of two cases

K. Kehoe, S. Weekx, S. Vermeiren, K. Ver Elst, T. Eyckmans, C. Schuermans, J. Lemmens


P.25 Ibrutinib-induced acrocyanosis

I. Dufour, G. Verstraete, J. Raedemaeker, F. Andreozzi, L. Bamps, S. Chabert, A. Sogorb, S. Bailly, E. Van den Neste, X. Theunssens, F. Tamirou, D. Tennstedt, A. Camboni, M-C. Vekemans


P.26 Waldenström's macroglobulinemia and renal insufficiency: a case report

S. Snauwaert, T. Lodewyck, P. De Paepe


P.27 IgM related AL amyloidosis: about 2 cases

J. Raedemaeker, F. Andreozzi, I. Dufour, L. Bamps, G. Verstraete, S. Chabert, S. Bailly, D. Maisin, J-P. Defour, A. Camboni, A-C. Pouleur, B. Gerber, F. Lecouvet, M-C. Vekemans


P.28 Multiple myeloma with extramedullary anaplastic transformation: a case report

K. Voet, J. Van Dorpe, P. Vlummens, D. Mazure


P.29 Polyneuropathy as presenting symptom of a nodal marginal zone lymphoma with monoclonal IgA- ? gammopathy: a case report

H. Maes, I. Geerts, M. Lefere, I. D'Hoore, P. Vermeylen, T. Tousseyn


P.30 The relation between the abnormality of the P53 gene and the epidemiological and biological parameters

A. Moueden, D. Benlaldj, F. Seghier


P.31 The relation between the abnormality of the P53 gene and the clinical and therapeutic parameters in chronic lymphoid leukemia

A. Moueden, D. Benlaldj, F. Seghier


P.32 Microcytic anemia: a rare presentation of Waldenström Macroglobulinemia

M. Gicart, M. Maerevoet, N. Meuleman


P.33 Myeloma cast nephropathy leading to early kidney allograft dysfunction: a case report

G. Verstraete, I. Dufour, J. Raedemaeker, F. Andreozzi, L. Bamps, S. Chabert, A. Sogorb, N. Kanaan, M. De Meyer, A. Buemi, S. Aydin, M-C. Vekemans


P.35 Fatal idiopathic hyperammonemia after induction chemotherapy for acute myeloid leukemia

E. Boulet, C. D'Angelo, M-F. Vincent, M. Komuta, P. Hantson, N. Straetmans


P.38 Five in a row - a cascade of hematological malignancies: a case report

N. Steinfort, M. Metsers, D. Breems, K.L. Wu, P. De schouwer, E. Heylen


P.14.2 KIT D816 mutation in myeloid neoplasms: look out for systemic mastocytosis associated hematologic neoplasms (SM-AHN)

E. Linskens, S. Van Landeghem, K. Vandepoele, K. Maes, I. Moors, J. Van Dorpe, C. Bonroy, K. Devreese, J. Philippé, B. Denys


O.5 Confirmation of the very low rate of subclinical venous thrombosis in people with hemophilia undergoing major orthopedic surgery in the absence of pharmacological thromboprophylaxis

G. Verstraete, C. Lambert, C. Hermans